# Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

> **NCT06984328** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Genmab** · enrollment: 1 (actual)

## Conditions studied

- Cutaneous Melanoma
- Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)
- Metastatic Cutaneous Melanoma (Stage IV)

## Interventions

- **BIOLOGICAL:** Acasunlimab
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06984328
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-25
- **Primary completion:** 2027-07-15
- **Final completion:** 2029-07-15
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06984328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06984328, "Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06984328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*